Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models.

Cell reports. Medicine·2026
Same author

An Analysis of Biomarkers for the Evaluation of Gene Therapy in Niemann-Pick Disease Type C1 Mice.

Human gene therapy·2026
Same author

Correction: Machine learning model for predicting the cold-heat pattern in Kampo medicine: a multicenter prospective observational study.

Frontiers in pharmacology·2026
Same author

Less Invasive Light Irradiation Methods for Inner Ear Gene Therapy Based on Photoswitch Technology: Toward Clinical Translation.

Human gene therapy·2026
Same author

Teneurin-4 in the nucleus accumbens modulates affective-like behaviors with potential effects on astrocytes in male mice.

Biochemical and biophysical research communications·2026
Same author

Spinal Shati/nat8l regulates mechanical hyperalgesia through NAAG-mGluR3 signaling in neuropathic pain.

Neuropharmacology·2026

Related Experiment Video

Updated: Jul 15, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

[Gene therapy for Parkinson's disease].

Shin-ichi Muramatsu1

  • 1Division of Neurology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, Japan.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|April 24, 2007
PubMed
Summary

Recombinant adeno-associated viral (rAAV) vectors show promise for Parkinson's disease (PD) gene therapy. Clinical trials are exploring rAAV for AADC, GABA, and neurturin delivery to restore dopamine and slow neurodegeneration.

Area of Science:

  • Neuroscience
  • Gene Therapy
  • Biotechnology

Context:

  • Parkinson's disease (PD) presents significant challenges for effective treatment.
  • Current therapies for PD have limitations in managing symptoms and disease progression.
  • Recombinant adeno-associated viral (rAAV) vectors offer a promising platform for in vivo gene delivery.

Purpose:

  • To evaluate the safety and efficacy of rAAV-mediated gene therapy for Parkinson's disease.
  • To explore different gene targets (AADC, GABA, neurturin) for PD treatment.
  • To assess the potential of rAAV vectors in restoring neurotransmitter balance and protecting neurons.

Summary:

  • Three Phase I clinical trials are investigating rAAV vectors for PD gene therapy.
  • One trial focuses on AADC gene transfer to enhance L-dopa efficacy.

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Jul 15, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

  • Another trial targets the subthalamic nucleus (STN) with GABA-expressing vectors, and a third delivers neurturin to protect dopaminergic neurons.
  • In vivo monitoring using PET tracers is employed to assess therapeutic effects.

    • Impact:

    • rAAV gene therapy demonstrates potential for reducing L-dopa dosage and prolonging symptom relief.
    • The STN-GABA strategy aims to modulate neuronal activity, similar to deep brain stimulation.
    • Neurturin delivery may slow the degeneration of crucial dopaminergic neurons.
    • While current trials report no serious adverse effects, regulated transgene expression systems are needed for enhanced safety.
    • rAAV gene therapy represents a potentially transformative approach for future PD treatment.